Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 99, Issue 6, 2007, Pages 442-450

  van Meerbeeck, Jan P ^a,c,i,j   Kramer, Gijs W P M ^b   Van Schil, Paul E Y ^b,c   Legrand, Catherine ^c   Smit, Egbert F ^d,e   Schramel, Franz ^f   Tjan Heijnen, Vivianne C ^g   Biesma, Bonne ^h   Debruyne, Channa ^c   van Zandwijk, Nico ⁱ   Splinter, Ted A W ^j   Giaccone, Giuseppe ^d,e  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Arnhems Radiotherapeutisch Instituut   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d EORTC DATA CENTER   (Belgium)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ESOPHAGITIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PNEUMONECTOMY; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34047270584     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk093     Document Type: Article

References (43)

1. Globocan 2002. Available at: http://www-dep.iarc.fr/. [Last accessed: May 14, 2006.]
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
3. Grunenwald D, Le Chevalier T. Stage IIIA category of non-small cell lung cancer: A new proposal. J Natl Cancer Inst 1997;89:88-9.
4. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-9.
5. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:1153-8.
6. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-80.
7. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis. Ann Thorac Surg 1992;53:992-8.
8. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Brit Med J 1995;311:899-909.
9. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages III (N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
10. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18:2658-64.
11. O'Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tian-Heijnen VC, et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). Eur J Cancer 2003;39:1416-22.
12. Biesma B, Manegold C, Smit HJM, Willems L, Legrand C, Passioukov A, et al. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer (EORTC 08984). Eur J Cancer 2006;42:1399-406.
13. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization; 1979 Report No.: World Health Organization Offset Publ No. 48.
14. Splinter TAW, Van Schil PE, Kramer GWPM, van Meerbeeck JP, Gregor A, Rocmans P, et al. A. Randomised trial of surgery versus radiotherapy in patients with stage IIIA (N2) non-small cell lung cancer after a response to induction-chemotherapy EORTC 08941. A study of the EORTC Lung Cancer Cooperative Group. Clin Lung Cancer 2000; 2:69-72.
15. Van Schil P, van Meerbeeck JP, Kramer G, Splinter T, Legrand C, Giaccone G, et al. Surgery after induction chemotherapy: Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Resp J 2005; 26:192-8.
16. ICRU report 50: Prescribing, recording and reporting photon beam therapy. Bethesda (MD): International Commission on Radiation Units and Measurements; 1993.
17. Kramer GWPM, Legrand CL, Van Schil P, Uitterhoeve L, Smit EF, Schramel F, et al. Quality assurance of thoracic radiotherapy in EORTC 08941: A randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. Eur J Cancer 2006;42:1391-8.
18. Williams J, Chen Y, Rubin P, Finkelstein J, Okunieff P. The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:182-8.
19. Van Meerbeeck JP, Kramer G, Van Schil P, Legrand C, O'Brien M, Manegold C, et al. Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): An analysis of different regimens used in EORTC 08941. Lung Cancer 2003;41:S79-80.
20. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:365-9.
21. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005;23:7014.
22. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: Proposed definition. Lung Cancer 2005;49:25-33.
23. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of cancer and leukemia group B protocol 8935. A multi institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995;109:473-85.
24. Kumar P, Herndon J, Sugarbaker D, Kohman L, Elias A, Green M. Long term survival outcome of a sequential trimodality trial in pathologically staged IIIA (N2) non-small cell lung cancer (NSCLC): Final results of Cancer and Leukemia Group B (CALGB) protocol 8935. Proc Am Soc Oncol 2000;10:1939.
25. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31.
26. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 2003;21:1752-9.
27. Liptay MJ, Fry WA. Complications from induction regimens for thoracic malignancies. Perioperative considerations. Chest Surg Clin N Am 1999;9:(1):79-95.
28. Van Meerbeeck JP, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer. Eur Respir J 2002;19:141-5.
29. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann Thorac Surg 2001;72:1149-54.
30. Birkmeyer JD. Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-27.
31. De Leyn P, Stroobants S, De Wever W, Lerut T, Coosemans W, Decker G, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: A Leuven Lung Cancer Group Study. J Clin Oncol 2006;24:3333-9.
32. Rami-Porta R. Induction chemotherapy: A surgeon's perspective. J Thor Oncol 2006;1:605-6.
33. Pisters KW, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. J Thorac Cardiovasc Surg 2000;119:429-39.
34. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;1:247-53.
35. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-34.
36. Thomas M, Macha HN, Ukena D, Hamm M, Deppermann M, Semik M, et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/ CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomised phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J Clin Oncol 2004;22S:7004.
37. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
38. Phase III randomized study of neoadjuvant Cisplatin and Docetaxal with versus without thoracic conformal radiotherapy followed by surgical resection and Docetaxal in patients with newly diagnosed favorable prognosis stage IIIA non-small cell lung cancer. Available at: http://www.cancer.gov/clinicaltrials/RTOG-0412. [Last accessed: February 11, 2007.]
39. Lagerwaard FJ, van de Vaart PJ, Voet PW, Nijssen-Visser MR, Schuchhard-Schipper RH, Joosten HP, et al. Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)? Lung Cancer 2002;38:297-301.
40. Liengswangwong V, Bonner JA, Shaw EG, Foote RL, Frytak S, Eagan RT, et al. Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994;12:496-502.
41. ElSharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003; 89:2184-9.
42. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004;(4):CD002140.pub2.
43. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatine (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. N Engl J Med 2005;352:2589-97.